Status:
UNKNOWN
Effects of GH on Body Proportions and Final Height in X-Linked Hypophosphatemic Rickets
Lead Sponsor:
University of Rostock
Conditions:
Hypophosphatemic Rickets
Growth Disorders
Eligibility:
All Genders
3-10 years
Phase:
PHASE1
Brief Summary
X-linked hypophosphatemic rickets (XLH) is characterized by rickets, disproportionate short stature, impaired renal phosphate reabsorption and vitamin D metabolism. Despite oral phosphate and vitamin ...
Eligibility Criteria
Inclusion
- Tanner stages of puberty B1, G1
- body height \< 2,5 SDS
- growth velocity \< 75%
- confirmed diagnosis of XLHR
- conservative treatment for at least 1 year (phosphate, vitamin D)
- informed consent, written agreement
Exclusion
- growth hormone deficiency
- hypothyreosis
- severe rickets
- severe physical deformities
- severe hyperparathyreoidism
- chronic renal failure
- complex syndrome involving failure to thrive
- chronic disease with failure to thrive
- impairment of glucose tolerance
- Tanner stages of puberty greater than B1, G1
- medical history of malignancy
- therapy with growth hormone, glucocorticoides, anabolica
- attending another clinical trial
Key Trial Info
Start Date :
August 1 2004
Trial Type :
INTERVENTIONAL
End Date :
August 1 2009
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00473187
Start Date
August 1 2004
End Date
August 1 2009
Last Update
May 14 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Childrens Hospital, Rostock
Rostock, Mecklenburg-Vorpommern, Germany, 18055